GlassScriptPhysician profile
Kayleigh Mcdaniel Litton
NPI 1588921407
$6,424.36
in general payments reported to CMS, 2019-2025
31 companies · $813 in 2025
The $813 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $489 · 2021: $359 · 2022: $679 · 2023: $1,495 · 2024: $847 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,907.96 | 2019-2025 | Avvigo Guidance System, Wolverine Coronary Cutting Balloon, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,180.19 | 2019-2025 | Lifevest |
| Abiomed | $579.54 | 2020-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $449.68 | 2019-2025 | |
| Abbott Laboratories | $373.96 | 2019-2023 | Optis |
| Amgen INC. | $322.79 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $300.47 | 2019-2023 | Xarelto |
| Medtronic, INC. | $183.84 | 2021-2025 | Symplicity G3, Onyx Frontier, Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.45 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $112.22 | 2019-2024 | |
| Pfizer INC. | $100.50 | 2019-2024 | |
| Cardiva Medical, INC. | $87.16 | 2024-2025 | Ensoetm, Savvywire |
| Inspire Medical Systems, INC. | $80.13 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $76.26 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $71.87 | 2024 | Arcalyst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $67.75 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $61.98 | 2019-2022 | |
| Atricure, INC. | $44.83 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $38.54 | 2019 | |
| Alnylam Pharmaceuticals INC. | $35.28 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.93 | 2023 | Arcalyst |
| Cardiovascular Systems INC. | $24.83 | 2019-2020 | |
| Daiichi Sankyo INC. | $23.68 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $23.38 | 2025 | Opsumit, Opsynvi, Uptravi |
| Baxter Healthcare | $21.48 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Dynavax Technologies Corporation | $17.07 | 2025 | Heplisav-B |
| Edwards Lifesciences Corporation | $16.55 | 2025 | |
| Amarin Pharma, INC. | $15.20 | 2019 | |
| Lundbeck LLC | $14.11 | 2019 | |
| Teleflex LLC | $13.83 | 2022 | |
| Irhythm Technologies, INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayleigh Litton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.